Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ETNBVery BullishM&Anews

High materiality10/10

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Sep 18, 2025, 1:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Acquisition signals strong industry confidence in ETNB's pipeline, reminiscent of successful past biotech acquisitions boosting share prices.

AI summary

What happened, with direct paths to the underlying reporting

Roche to acquire 89bio for up to $3.5 billion. Deal focuses on liver and cardiometabolic disease treatments.

Roche to acquire 89bio for up to $3.5 billion.
Deal focuses on liver and cardiometabolic disease treatments.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Roche to Acquire 89bio in $3.5 Billion Deal for Liver Drug Development